Alkem Laboratories has informed that the Company today announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partialonset seizures in adult patients. A press release in this regard is enclosed.
The above information is a part of company’s filings submitted to BSE.